focus -WSS

focus

author：knowledge 2025-08-24 04:03:19 - browse：8687

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Trans patients at the end of life deserve respect and dignity

hotspot

WSS

Vivek Ramaswamy made waves in the debate, much as in biotech

Can U.S. cancer drug shortages be fixed?

Gene therapy has helped boys walk. Can scientists keep it that way?

How to make over

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Weight bias in eating disorder treatment complicated by new weight loss drugs

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Tori Bowie and the unacceptable rates of Black maternal death

Death of patient in Alzheimer’s trial raises question of possible risks

As demand for Covid shots wanes, Moderna seeks its next success

Republicans love RFK Jr. What's that tell us about health in 2024?

Sports medicine is finally prioritizing gender equality

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Moonlake's readout produced a cash windfall. Risks remain

Ask STAT: What do you want to know about ChatGPT in medicine?

23andMe had bad news about my health. I wish a person had delivered it

The science behind Janet Jackson's pregnancy at 49

explore

PBMs are inflating the cost of generic drugs. They must be reined in

Kellogg’s is going to war over Mexico’s nutrition label rules

People can get long Covid without testing positive for virus: Study

3 hurdles to bringing medical devices to the U.S. market

Disclosing genetic information: not as worrisome as once feared

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

focus

hotspot

hotspot

entertainment